Eloxx Pharmaceuticals, Inc.
ELOXD
OTC PK
| 03/31/2026 | 03/31/2025 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -24.40M | -30.68M | -36.07M |
| Total Depreciation and Amortization | -- | -- | 738.00K | 683.00K | 695.00K |
| Total Amortization of Deferred Charges | -- | -- | 450.00K | 537.00K | 541.00K |
| Total Other Non-Cash Items | -- | -- | 2.90M | 2.93M | 3.10M |
| Change in Net Operating Assets | -- | -- | -1.18M | -2.64M | -118.00K |
| Cash from Operations | -- | -- | -21.49M | -29.17M | -31.85M |
| Capital Expenditure | -- | -- | -48.00K | -55.00K | -66.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 25.00K | 11.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -23.00K | -44.00K | -66.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -7.50M | -7.50M | -- |
| Issuance of Common Stock | -- | -- | 1.43M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 1.81M | 1.81M | 8.81M |
| Cash from Financing | -- | -- | -4.26M | -5.69M | 8.81M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -25.77M | -34.90M | -23.10M |